Janssen Research and Development LLC New Twoyear Guselkumab Data Show Patients with Moderate to Severe Plaque Psoriasis Achieved Consistent Rates of Skin Clearance

GENEVA Switzerland Sept. 16 2017 PRNewswire More than 80 percent of patients receiving guselkumab including patients transitioned from HUMIRAÂ adalimumab to the antiinterleukin IL23 monoclonal antibody demonstrated PASI 90 and IGA 01 scores at week 1...